01 Dec 2023
PBS arrangements due to discontinuation of the Ordine brands of morphine hydrochloride trihydrate oral liquids effective 1 December 2023
Two new temporarily PBS listings for morphine sulfate will be effective from 1 December 2023. These new products are being listed to address the deletion from the Australian market of morphine hydrochloride trihydrate oral liquids (brand: Ordine).
01 Dec 2023
1 December 2023 Changes to the PBS Listings of Medicines for the Treatment of Ankylosing Spondylitis
On 1 December 2023, changes will be made to the authority requirements of the following biological medicines listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of ankylosing spondylitis – adalimumab, etanercept and infliximab.
22 Nov 2023
Agenda for the March 2024 PBAC meeting – 22 November 2023
Agenda for the March 2024 PBAC meeting – 22 November 2023
22 Nov 2023
Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert paper published
Updates to the HTA Review Research and Analysis papers collection: Draft HTA expert paper published
16 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 16 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 16 November 2023
10 Nov 2023
Updates to the HTA Review: Consultation 1 report published
Updates to the HTA Review: Consultation 1 report published
09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 9 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 9 November 2023
06 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee – 3 November 2023
Updates to the HTA Policy and Methods Review Reference Committee – 3 November 2023
01 Nov 2023
PBS arrangements during shortage of amoxicillin and clavulanate potassium 400 mg/57 mg per 5 mL oral suspension effective 1 November 2023
Due to the shortage of Curam Duo (amoxicillin 400 mg/5 mL + clavulanic acid 57 mg/5 mL powder for oral liquid, 60 mL)